Literature DB >> 10626106

Old, new, and emerging therapies for atopic dermatitis.

R Sidbury1, J M Hanifin.   

Abstract

Atopic dermatitis is the most common skin condition in children under the age of 11 years. The chronic, cyclical, pruritic course of AD exacts a huge financial and emotional toll on its sufferers. Confusion about appropriate skin care and the role of allergic factors further complicates management. Although diligent moisturization and judicious use of topical steroids remain the therapeutic standard, new, effective local and systemic agents are now available, and several promising nonsteroidal products may be available soon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10626106     DOI: 10.1016/s0733-8635(05)70141-8

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  5 in total

Review 1.  Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.

Authors:  Keri Wellington; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids.

Authors:  F S Kalthoff; J Chung; P Musser; A Stuetz
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

3.  Acupuncture for patients with atopic dermatitis: A systematic review protocol.

Authors:  Yijiang Liu; Hai Cui; Ruosang Du; Lu Zhang; Hongwen Yuan; Xiaohui Zhang; Shumei Zheng
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

4.  Effects of Hyeonggaeyeongyo-tang in ovalbumin-induced allergic rhinitis model.

Authors:  Se Hyang Hong; Soon Re Kim; Han-Seok Choi; Jin Mo Ku; Hye Sook Seo; Yong Cheol Shin; Seong-Gyu Ko
Journal:  Mediators Inflamm       Date:  2014-06-26       Impact factor: 4.711

Review 5.  Immune surveillance in the skin: mechanisms and clinical consequences.

Authors:  Thomas S Kupper; Robert C Fuhlbrigge
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.